Boston Scientific Corporation (BSX) is Reiterated by Wedbush to Neutral, Raises Price Target to $ 25

Boston Scientific Corporation (BSX) was Reiterated by Wedbush to “Neutral” according to the research note released today. The brokerage firm has raised the Price Target to $ 25 from a previous price target of $23 . Wedbush advised their investors in a research report released on Jul 29, 2016.

Many Wall Street Analysts have commented on Boston Scientific Corporation. Company shares were Reiterated by The Benchmark Company on Jul 28, 2016 to “Buy”, Firm has raised the Price Target to $ 31 from a previous price target of $25 .Boston Scientific Corporation was Initiated by Guggenheim to “Buy” on Jun 9, 2016.

On the company’s financial health, Boston Scientific Corporation reported $0.27 EPS for the quarter, based on the information available during the earnings call on Jul 28, 2016. Analyst had a consensus estimate of $0.27. The company had revenue of $2126.00 million for the quarter, compared to analysts expectations of $2044.88 million. The company’s revenue was up 15.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.22 EPS.

Boston Scientific Corporation opened for trading at $24.44 and hit $24.79 on the upside on Thursday, eventually ending the session at $24.34, with a gain of 2.87% or 0.68 points. The heightened volatility saw the trading volume jump to 2,42,80,806 shares. Company has a market cap of $33,026 M.

In a different news, on Jul 20, 2016, David A Pierce (SVP and President, Endoscopy) sold 2,480 shares at $24.03 per share price. According to the SEC, on Jul 20, 2016, Michael P. Phalen (EVP & President, MedSurg) sold 35,000 shares at $24.03 per share price. On Jul 5, 2016, Timothy A. Pratt (EVP, GC & Chief Admin Officer) sold 24,000 shares at $23.39 per share price, according to the Form-4 filing with the securities and exchange commission.

Boston Scientific Corporation develops manufactures and markets medical devices. The Company offers its products by seven core businesses: Interventional Cardiology which includes Drug-Eluting Coronary Stent Systems Intravascular Imaging devised and Coronary Technology products such as guide wires guide catheters and balloon catheters among others; Peripheral Interventions (PI) which include stents balloon catheters wires peripheral embolization devices and vena cava filters; Cardiac Rhythm Management (CRM) which include implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities; Electrophysiology (EP) which include steerable RF ablation catheters intracardiac ultrasound catheters diagnostic catheters delivery sheaths and other accessories; Endoscopy which includes Spyglass System WallFlex Colonic Stents Resolution Clip and Expect Aspiration Needle among others; Urology and Women’s Health and Neuromodulation.

Boston Scientific Corporation

Leave a Reply

Boston Scientific Corporation - Is it time to Sell?

Top Brokerage Firms are advising their investors on Boston Scientific Corporation. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.